We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Sandra M. Swain, M.D...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for...
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO...
– Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing...
Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.53 | -20.4519119351 | 17.26 | 17.6 | 13.7 | 1116914 | 15.02431467 | CS |
4 | -11.08 | -44.6594115276 | 24.81 | 24.92 | 13.7 | 795521 | 18.09052132 | CS |
12 | -2.75 | -16.6868932039 | 16.48 | 30.958 | 13.7 | 810812 | 21.97984347 | CS |
26 | 4.86 | 54.7914317926 | 8.87 | 30.958 | 6.93 | 526750 | 19.14945335 | CS |
52 | 8.16 | 146.499102334 | 5.57 | 30.958 | 4.44 | 337867 | 16.60936412 | CS |
156 | -17.73 | -56.3572790846 | 31.46 | 32.4476 | 2.09 | 190950 | 15.81642408 | CS |
260 | -1.93 | -12.3243933589 | 15.66 | 63.78 | 2.09 | 185911 | 17.73971744 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions